CDCP1 physically interacts with MET (Figure 2), particularly in contexts like squamous cell carcinoma, where this interaction contributes to resistance to EGFR inhibitors and promotes tumor growth, metastasis, and therapy resistance. Here, EGFR is linked to neoplasm.